Studies Exhibit Less Involvement of Genetics in Shaping the Microbiome Ecology of a Human Being
Date : Mar 12, 2018 Author : PMR Editorial Staff Category : Healthcare
Global Microbiome Therapeutics Market to Register an Exponential CAGR of 62.9% Between 2018 and 2025
A new study challenges the age-old theory believed by people on variations in the human microbiome. According to this research, genes do not play a major role in shaping the microbiome of person. These microbiomes are almost similar and vary by just 2% among people. It has been observed over the years that human microbiome has also evolved with time. It includes viruses, bacteria, fungi, Achaeans, etc. Currently, the microbiome is considered as a major part of the human body and has the potential to create a significant impact on the human body.
Microbiome therapeutics has grown to become a huge market in today’s day and age. This includes the different therapies that are used to deal with unhealthy microbial networks and improve the growth of healthy microbiomes. It was earlier believed that these human microbiomes differ from person to person based on their genetic behavior. However, the recent study on this subject opposes this belief and also reveals the connection of microbiomes with human health. According to the research report, most of our microbiomes are under the influence of the external environment. Gut microbiome is one of the principal focus areas. It has been revealed that a disturbance in the gut microbiota can lead to severe health concerns. These effects may include conditions like irritable bowel or inflammatory bowel problems and even diseases like obesity or Type 2 diabetes.
According to a new market study conducted by Persistence Market Research, the global microbiome therapeutics market is projected to grow at a stellar CAGR of 62.9% during the study period of 2018-2025. However, there aren’t any marketed or promoted therapeutics in the global market and it is anticipated that the very first drug will be launched later in 2018.
Relevance of Microbiome with Human Health to Boost Development of Microbiome Therapeutics
There are also indications of a link between microbial population and the health of people denoted by levels of cholesterol, weight of a person, blood glucose levels, etc. This in turn enables the identification of common health problems with the help of microbiomes as well as factors influencing their population. The growing advancements taking place in the study of human microbiomes can result in a better understanding and development of therapies for treating unhealthy microbial networks. The negative changes taking place in microbiome composition is a condition known as dysbiosis, which is associated with various problems in a human body such as allergies, asthma, autism, colon cancer, etc. Such health related severities associated with dysbiosis are triggering the growth in revenue of the microbiome therapeutics market across the world.
There are more than 25 companies that are leading the global microbiome therapeutics market with their portfolio of 120 drugs that are somewhere in the development stages and are still in the pipeline. The report further highlights the different indication types in the microbiome therapeutics market that dominate the global market and also throws light on the various regions that exhibit the highest demand for microbiome therapeutics.